Zai Lab is a global biopharmaceutical company founded in 2014 and based in China and the U.S.. Led by Chairperson and CEO Dr. Samantha Du, the company now has more than 2,000 employees internationally.
Focusing on developing novel therapies for oncology, autoimmune disorders, infectious diseases, and neurological disorders, it has built a broad pipeline of late-stage drug candidates, five of which have been approved and launched in China. The company also has internal research and development capabilities to advance its discovery pipeline.
The company is strategically partnering with prominent biopharma organizations such as Amgen, GSK, Seagen, BMS, Mirati and Deciphera. Concurrently, Zai Lab is building a proprietary pipeline across therapeutic areas such asoncology, autoimmune disorders, infectious diseases, and neuroscience.
In this email Q&A, we heard from Josh Smiley, president and chief operating officer of Zai Lab, and Dr. Harald Reinhart, pre…